Cliff Asness's CHRS Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 1.21 M shares of Coherus Oncology, Inc. (CHRS) worth $2.04 M, representing 0.00% of the portfolio. First purchased in 2017-Q1, this long-term strategic position has been held for 34 quarters.
Based on 13F filings, Cliff Asness has maintained a strategic position in CHRS, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2024, adding 799,712 shares. Largest reduction occurred in Q1 2025, reducing 546,569 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Coherus Oncology (CHRS) Holding Value Over Time
Track share changes against reported price movement
Quarterly Coherus Oncology (CHRS) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +320,326 | Add 36.17% | 1.21 M | $1.69 |
| Q4 2025 | -17,317 | Reduce 1.92% | 885,720 | $1.42 |
| Q3 2025 | +134,116 | Add 17.44% | 903,037 | $1.64 |
| Q2 2025 | +100,956 | Add 15.11% | 768,921 | $0.73 |
| Q1 2025 | -546,569 | Reduce 45.00% | 667,965 | $0.81 |
| Q4 2024 | -305,177 | Reduce 20.08% | 1.21 M | $1.38 |
| Q3 2024 | +799,712 | Add 111.07% | 1.52 M | $1.04 |
| Q2 2024 | +719,999 | New Buy | 719,999 | $1.73 |
| Q1 2024 | -371,366 | Sold Out | 0 | $0.00 |
| Q4 2023 | +330,233 | Add 802.84% | 371,366 | $3.33 |
| Q3 2023 | -2,083 | Reduce 4.82% | 41,133 | $3.74 |
| Q2 2023 | -27,000 | Reduce 38.45% | 43,216 | $4.27 |
| Q1 2023 | -14,776 | Reduce 17.39% | 70,216 | $6.84 |
| Q4 2022 | +47,670 | Add 127.73% | 84,992 | $7.92 |
| Q3 2022 | -8,560 | Reduce 18.66% | 37,322 | $9.62 |
| Q2 2022 | -31,826 | Reduce 40.96% | 45,882 | $7.24 |
| Q1 2022 | +60,442 | Add 350.06% | 77,708 | $12.91 |
| Q4 2021 | -2,564 | Reduce 12.93% | 17,266 | $15.99 |
| Q3 2021 | -7,177 | Reduce 26.57% | 19,830 | $16.09 |
| Q2 2021 | -84,533 | Reduce 75.79% | 27,007 | $13.85 |
| Q1 2021 | +16,187 | Add 16.98% | 111,540 | $14.61 |
| Q4 2020 | -16,945 | Reduce 15.09% | 95,353 | $17.38 |
| Q3 2020 | -107,796 | Reduce 48.98% | 112,298 | $18.34 |
| Q2 2020 | +128,672 | Add 140.75% | 220,094 | $17.86 |
| Q1 2020 | +54,237 | Add 145.86% | 91,422 | $16.22 |
| Q4 2019 | +19,254 | Add 107.38% | 37,185 | $18.02 |
| Q3 2019 | +3,567 | Add 24.83% | 17,931 | $20.24 |
| Q2 2019 | -8,903 | Reduce 38.26% | 14,364 | $22.07 |
| Q1 2019 | -16,158 | Reduce 40.98% | 23,267 | $13.62 |
| Q4 2018 | +39,425 | New Buy | 39,425 | $9.06 |
| Q4 2017 | -26,915 | Sold Out | 0 | $0.00 |
| Q3 2017 | +13,015 | Add 93.63% | 26,915 | $13.34 |
| Q2 2017 | -3,029 | Reduce 17.89% | 13,900 | $14.32 |
| Q1 2017 | +16,929 | New Buy | 16,929 | $21.15 |
Cliff Asness's Coherus Oncology Investment FAQs
Cliff Asness first purchased Coherus Oncology, Inc. (CHRS) in Q1 2017, acquiring 16,929 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Coherus Oncology, Inc. (CHRS) for 34 quarters since Q1 2017.
Cliff Asness's largest addition to Coherus Oncology, Inc. (CHRS) was in Q3 2024, adding 1,519,711 shares worth $1.58 M.
According to the latest 13F filing for Q1 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 1,206,046 shares of Coherus Oncology, Inc. (CHRS), valued at approximately $2.04 M.
As of the Q1 2026 filing, Coherus Oncology, Inc. (CHRS) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Coherus Oncology, Inc. (CHRS) was 1,519,711 shares, as reported at the end of Q3 2024.